Please assess the completion status of the following clinical trial:

Trial Title: A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Screening laboratory result indicating Hepatitis C Virus (HCV) Genotype (GT) 1-6 infection.~* Positive plasma HCV antibody and HCV RNA viral load greater than or equal to 1000 IU/mL at Screening.~* Treatment-naive to any approved or investigational anti-HCV medication.~* Participant must be documented as cirrhotic, with a Child-Pugh score of less than or equal to 6.~Exclusion Criteria:~* Female participant who is pregnant, breastfeeding or is considering becoming pregnant during the study, or for approximately 30 days after the last dose of study drug.~* Any current or historical clinical evidence of decompensated cirrhosis.~* Positive test result at Screening for hepatitis B surface antigen (HBsAg), HBV deoxyribonucleic acid \> lower limit of quantification (LLOQ) in subjects with isolated positive antibody to hepatitis B core antigen (anti-HBc) (i.e., negative HBsAg and anti-hepatitis B),or anti human immunodeficiency virus antibody (HIV Ab).~* HCV genotype performed by the central laboratory during screening indicating co-infection with more than one HCV genotype.~* History of suspected or confirmed hepatocellular carcinoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks (Type: EXPERIMENTAL): Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).